nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABCG2—Cladribine—multiple sclerosis	0.112	0.252	CbGbCtD
Afatinib—ABCG2—Mitoxantrone—multiple sclerosis	0.082	0.184	CbGbCtD
Afatinib—ABCG2—Dexamethasone—multiple sclerosis	0.0425	0.0954	CbGbCtD
Afatinib—ABCB1—Methylprednisolone—multiple sclerosis	0.0405	0.0909	CbGbCtD
Afatinib—ABCG2—Methotrexate—multiple sclerosis	0.0342	0.0766	CbGbCtD
Afatinib—ABCB1—Mitoxantrone—multiple sclerosis	0.0296	0.0663	CbGbCtD
Afatinib—ABCB1—Betamethasone—multiple sclerosis	0.0264	0.0591	CbGbCtD
Afatinib—ABCB1—Prednisolone—multiple sclerosis	0.026	0.0583	CbGbCtD
Afatinib—ABCB1—Prednisone—multiple sclerosis	0.0246	0.0551	CbGbCtD
Afatinib—ABCB1—Dexamethasone—multiple sclerosis	0.0153	0.0344	CbGbCtD
Afatinib—ABCB1—Methotrexate—multiple sclerosis	0.0123	0.0276	CbGbCtD
Afatinib—PHKG2—brainstem—multiple sclerosis	0.00428	0.0515	CbGeAlD
Afatinib—ERBB4—brainstem—multiple sclerosis	0.00385	0.0463	CbGeAlD
Afatinib—DYRK1A—brainstem—multiple sclerosis	0.0037	0.0446	CbGeAlD
Afatinib—PHKG2—medulla oblongata—multiple sclerosis	0.00298	0.0359	CbGeAlD
Afatinib—ERBB4—medulla oblongata—multiple sclerosis	0.00268	0.0323	CbGeAlD
Afatinib—ERBB4—midbrain—multiple sclerosis	0.00245	0.0295	CbGeAlD
Afatinib—ERBB4—spinal cord—multiple sclerosis	0.00239	0.0288	CbGeAlD
Afatinib—EPHA6—nervous system—multiple sclerosis	0.00232	0.028	CbGeAlD
Afatinib—HIPK4—brain—multiple sclerosis	0.00225	0.027	CbGeAlD
Afatinib—PHKG2—nervous system—multiple sclerosis	0.00224	0.027	CbGeAlD
Afatinib—EPHA6—central nervous system—multiple sclerosis	0.00224	0.0269	CbGeAlD
Afatinib—PHKG2—central nervous system—multiple sclerosis	0.00216	0.026	CbGeAlD
Afatinib—PHKG2—cerebellum—multiple sclerosis	0.00211	0.0254	CbGeAlD
Afatinib—ERBB2—nervous system—multiple sclerosis	0.00202	0.0243	CbGeAlD
Afatinib—ERBB4—nervous system—multiple sclerosis	0.00202	0.0243	CbGeAlD
Afatinib—ERBB2—central nervous system—multiple sclerosis	0.00194	0.0234	CbGeAlD
Afatinib—ERBB4—central nervous system—multiple sclerosis	0.00194	0.0234	CbGeAlD
Afatinib—DYRK1A—nervous system—multiple sclerosis	0.00194	0.0233	CbGeAlD
Afatinib—ERBB2—cerebellum—multiple sclerosis	0.0019	0.0228	CbGeAlD
Afatinib—ERBB4—cerebellum—multiple sclerosis	0.0019	0.0228	CbGeAlD
Afatinib—DYRK1A—central nervous system—multiple sclerosis	0.00187	0.0225	CbGeAlD
Afatinib—IRAK1—midbrain—multiple sclerosis	0.00183	0.0221	CbGeAlD
Afatinib—DYRK1A—cerebellum—multiple sclerosis	0.00183	0.022	CbGeAlD
Afatinib—EPHA6—brain—multiple sclerosis	0.00178	0.0214	CbGeAlD
Afatinib—PHKG2—brain—multiple sclerosis	0.00171	0.0206	CbGeAlD
Afatinib—ABL1—brainstem—multiple sclerosis	0.00161	0.0194	CbGeAlD
Afatinib—EGFR—cerebellum—multiple sclerosis	0.00161	0.0193	CbGeAlD
Afatinib—ABL1—retina—multiple sclerosis	0.00156	0.0187	CbGeAlD
Afatinib—ERBB4—brain—multiple sclerosis	0.00154	0.0185	CbGeAlD
Afatinib—ERBB2—brain—multiple sclerosis	0.00154	0.0185	CbGeAlD
Afatinib—DYRK1A—brain—multiple sclerosis	0.00148	0.0178	CbGeAlD
Afatinib—IRAK1—cerebellum—multiple sclerosis	0.00142	0.0171	CbGeAlD
Afatinib—EGFR—brain—multiple sclerosis	0.00131	0.0157	CbGeAlD
Afatinib—IRAK1—brain—multiple sclerosis	0.00115	0.0139	CbGeAlD
Afatinib—ABL1—medulla oblongata—multiple sclerosis	0.00112	0.0135	CbGeAlD
Afatinib—ABL1—midbrain—multiple sclerosis	0.00103	0.0124	CbGeAlD
Afatinib—ABL1—spinal cord—multiple sclerosis	0.001	0.0121	CbGeAlD
Afatinib—ABL1—nervous system—multiple sclerosis	0.000845	0.0102	CbGeAlD
Afatinib—ERBB2—Exemestane—Methylprednisolone—multiple sclerosis	0.000824	0.119	CbGdCrCtD
Afatinib—ABL1—central nervous system—multiple sclerosis	0.000813	0.00978	CbGeAlD
Afatinib—ABL1—cerebellum—multiple sclerosis	0.000795	0.00956	CbGeAlD
Afatinib—Infestation—Azathioprine—multiple sclerosis	0.000767	0.00439	CcSEcCtD
Afatinib—Mediastinal disorder—Cladribine—multiple sclerosis	0.000763	0.00437	CcSEcCtD
Afatinib—Asthenia—Fingolimod—multiple sclerosis	0.000762	0.00436	CcSEcCtD
Afatinib—ERBB2—Exemestane—Prednisone—multiple sclerosis	0.000752	0.109	CbGdCrCtD
Afatinib—Pruritus—Fingolimod—multiple sclerosis	0.000751	0.0043	CcSEcCtD
Afatinib—Alopecia—Cladribine—multiple sclerosis	0.000749	0.00429	CcSEcCtD
Afatinib—Dehydration—Mitoxantrone—multiple sclerosis	0.000749	0.00428	CcSEcCtD
Afatinib—Mental disorder—Cladribine—multiple sclerosis	0.000742	0.00425	CcSEcCtD
Afatinib—Malnutrition—Cladribine—multiple sclerosis	0.000737	0.00422	CcSEcCtD
Afatinib—ERBB2—Exemestane—Prednisolone—multiple sclerosis	0.000734	0.106	CbGdCrCtD
Afatinib—Hypokalaemia—Mitoxantrone—multiple sclerosis	0.000733	0.00419	CcSEcCtD
Afatinib—Diarrhoea—Fingolimod—multiple sclerosis	0.000726	0.00416	CcSEcCtD
Afatinib—Hepatobiliary disease—Azathioprine—multiple sclerosis	0.000726	0.00415	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Mitoxantrone—multiple sclerosis	0.000725	0.00415	CcSEcCtD
Afatinib—Back pain—Cladribine—multiple sclerosis	0.000713	0.00408	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Mitoxantrone—multiple sclerosis	0.00071	0.00406	CcSEcCtD
Afatinib—ABCG2—medulla oblongata—multiple sclerosis	0.000709	0.00853	CbGeAlD
Afatinib—Dizziness—Fingolimod—multiple sclerosis	0.000702	0.00402	CcSEcCtD
Afatinib—Dry eye—Dexamethasone—multiple sclerosis	0.000701	0.00401	CcSEcCtD
Afatinib—Dry eye—Betamethasone—multiple sclerosis	0.000701	0.00401	CcSEcCtD
Afatinib—Headache—Fingolimod—multiple sclerosis	0.000665	0.00381	CcSEcCtD
Afatinib—ABCG2—midbrain—multiple sclerosis	0.000648	0.0078	CbGeAlD
Afatinib—Upper respiratory tract infection—Mitoxantrone—multiple sclerosis	0.000647	0.0037	CcSEcCtD
Afatinib—ABL1—brain—multiple sclerosis	0.000646	0.00777	CbGeAlD
Afatinib—Cough—Cladribine—multiple sclerosis	0.000644	0.00368	CcSEcCtD
Afatinib—ABCG2—spinal cord—multiple sclerosis	0.000632	0.00761	CbGeAlD
Afatinib—Weight decreased—Mitoxantrone—multiple sclerosis	0.000629	0.0036	CcSEcCtD
Afatinib—Pneumonia—Mitoxantrone—multiple sclerosis	0.000624	0.00357	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.000624	0.00357	CcSEcCtD
Afatinib—Mediastinal disorder—Azathioprine—multiple sclerosis	0.000621	0.00355	CcSEcCtD
Afatinib—Renal failure—Mitoxantrone—multiple sclerosis	0.00061	0.00349	CcSEcCtD
Afatinib—Alopecia—Azathioprine—multiple sclerosis	0.000609	0.00348	CcSEcCtD
Afatinib—Dry skin—Prednisolone—multiple sclerosis	0.000605	0.00346	CcSEcCtD
Afatinib—Stomatitis—Mitoxantrone—multiple sclerosis	0.000605	0.00346	CcSEcCtD
Afatinib—Conjunctivitis—Mitoxantrone—multiple sclerosis	0.000603	0.00345	CcSEcCtD
Afatinib—Urinary tract infection—Mitoxantrone—multiple sclerosis	0.000603	0.00345	CcSEcCtD
Afatinib—Infection—Cladribine—multiple sclerosis	0.000598	0.00342	CcSEcCtD
Afatinib—Nervous system disorder—Cladribine—multiple sclerosis	0.00059	0.00338	CcSEcCtD
Afatinib—Skin disorder—Cladribine—multiple sclerosis	0.000585	0.00335	CcSEcCtD
Afatinib—Sepsis—Prednisone—multiple sclerosis	0.000574	0.00328	CcSEcCtD
Afatinib—Insomnia—Cladribine—multiple sclerosis	0.000544	0.00312	CcSEcCtD
Afatinib—Cystitis noninfective—Methotrexate—multiple sclerosis	0.00054	0.00309	CcSEcCtD
Afatinib—Dyspnoea—Cladribine—multiple sclerosis	0.000537	0.00307	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Methylprednisolone—multiple sclerosis	0.000534	0.00306	CcSEcCtD
Afatinib—Cystitis—Methotrexate—multiple sclerosis	0.000533	0.00305	CcSEcCtD
Afatinib—Decreased appetite—Cladribine—multiple sclerosis	0.000523	0.00299	CcSEcCtD
Afatinib—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.00052	0.00297	CcSEcCtD
Afatinib—Fatigue—Cladribine—multiple sclerosis	0.000519	0.00297	CcSEcCtD
Afatinib—Constipation—Cladribine—multiple sclerosis	0.000515	0.00295	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000507	0.0029	CcSEcCtD
Afatinib—Dry skin—Dexamethasone—multiple sclerosis	0.000505	0.00289	CcSEcCtD
Afatinib—Dry skin—Betamethasone—multiple sclerosis	0.000505	0.00289	CcSEcCtD
Afatinib—Hypokalaemia—Dexamethasone—multiple sclerosis	0.000501	0.00287	CcSEcCtD
Afatinib—Hypokalaemia—Betamethasone—multiple sclerosis	0.000501	0.00287	CcSEcCtD
Afatinib—ABCG2—cerebellum—multiple sclerosis	0.000501	0.00603	CbGeAlD
Afatinib—Bladder pain—Methotrexate—multiple sclerosis	0.000499	0.00286	CcSEcCtD
Afatinib—Mouth ulceration—Methotrexate—multiple sclerosis	0.000499	0.00286	CcSEcCtD
Afatinib—Conjunctivitis—Prednisolone—multiple sclerosis	0.000495	0.00283	CcSEcCtD
Afatinib—Alopecia—Mitoxantrone—multiple sclerosis	0.000492	0.00282	CcSEcCtD
Afatinib—Upper respiratory tract infection—Triamcinolone—multiple sclerosis	0.000488	0.00279	CcSEcCtD
Afatinib—Infection—Azathioprine—multiple sclerosis	0.000486	0.00278	CcSEcCtD
Afatinib—ABCB1—retina—multiple sclerosis	0.000484	0.00582	CbGeAlD
Afatinib—Sepsis—Methotrexate—multiple sclerosis	0.000479	0.00274	CcSEcCtD
Afatinib—Body temperature increased—Cladribine—multiple sclerosis	0.000476	0.00272	CcSEcCtD
Afatinib—Skin disorder—Azathioprine—multiple sclerosis	0.000475	0.00272	CcSEcCtD
Afatinib—Dysgeusia—Mitoxantrone—multiple sclerosis	0.000475	0.00272	CcSEcCtD
Afatinib—Back pain—Mitoxantrone—multiple sclerosis	0.000469	0.00268	CcSEcCtD
Afatinib—Infestation—Methylprednisolone—multiple sclerosis	0.000467	0.00267	CcSEcCtD
Afatinib—Infestation NOS—Methylprednisolone—multiple sclerosis	0.000467	0.00267	CcSEcCtD
Afatinib—Conjunctivitis—Triamcinolone—multiple sclerosis	0.000455	0.0026	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Methylprednisolone—multiple sclerosis	0.000449	0.0651	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Betamethasone—multiple sclerosis	0.000442	0.0641	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Dexamethasone—multiple sclerosis	0.000442	0.0641	CbGdCrCtD
Afatinib—Epistaxis—Triamcinolone—multiple sclerosis	0.000441	0.00253	CcSEcCtD
Afatinib—Dry skin—Prednisone—multiple sclerosis	0.00044	0.00252	CcSEcCtD
Afatinib—Hypokalaemia—Prednisone—multiple sclerosis	0.000437	0.0025	CcSEcCtD
Afatinib—Asthenia—Cladribine—multiple sclerosis	0.000432	0.00247	CcSEcCtD
Afatinib—Weight decreased—Dexamethasone—multiple sclerosis	0.000431	0.00247	CcSEcCtD
Afatinib—Weight decreased—Betamethasone—multiple sclerosis	0.000431	0.00247	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Methylprednisolone—multiple sclerosis	0.000426	0.0618	CbGdCrCtD
Afatinib—Pruritus—Cladribine—multiple sclerosis	0.000426	0.00244	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Prednisone—multiple sclerosis	0.000423	0.00242	CcSEcCtD
Afatinib—Cough—Mitoxantrone—multiple sclerosis	0.000423	0.00242	CcSEcCtD
Afatinib—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000422	0.00242	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Dexamethasone—multiple sclerosis	0.000419	0.0608	CbGdCrCtD
Afatinib—ERBB2—Desoximetasone—Betamethasone—multiple sclerosis	0.000419	0.0608	CbGdCrCtD
Afatinib—Conjunctivitis—Dexamethasone—multiple sclerosis	0.000413	0.00236	CcSEcCtD
Afatinib—Conjunctivitis—Betamethasone—multiple sclerosis	0.000413	0.00236	CcSEcCtD
Afatinib—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000412	0.00236	CcSEcCtD
Afatinib—Diarrhoea—Cladribine—multiple sclerosis	0.000412	0.00236	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Triamcinolone—multiple sclerosis	0.00041	0.0594	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Prednisone—multiple sclerosis	0.00041	0.0594	CbGdCrCtD
Afatinib—ABCG2—brain—multiple sclerosis	0.000407	0.0049	CbGeAlD
Afatinib—ERBB2—Triamcinolone—Prednisolone—multiple sclerosis	0.0004	0.058	CbGdCrCtD
Afatinib—Dizziness—Cladribine—multiple sclerosis	0.000398	0.00228	CcSEcCtD
Afatinib—Infection—Mitoxantrone—multiple sclerosis	0.000393	0.00225	CcSEcCtD
Afatinib—Eye disorder—Methylprednisolone—multiple sclerosis	0.000392	0.00224	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Prednisone—multiple sclerosis	0.000389	0.0564	CbGdCrCtD
Afatinib—Body temperature increased—Azathioprine—multiple sclerosis	0.000387	0.00221	CcSEcCtD
Afatinib—Skin disorder—Mitoxantrone—multiple sclerosis	0.000384	0.0022	CcSEcCtD
Afatinib—Vomiting—Cladribine—multiple sclerosis	0.000383	0.00219	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Prednisolone—multiple sclerosis	0.00038	0.0551	CbGdCrCtD
Afatinib—Rash—Cladribine—multiple sclerosis	0.000379	0.00217	CcSEcCtD
Afatinib—Dermatitis—Cladribine—multiple sclerosis	0.000379	0.00217	CcSEcCtD
Afatinib—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000378	0.00216	CcSEcCtD
Afatinib—Headache—Cladribine—multiple sclerosis	0.000377	0.00216	CcSEcCtD
Afatinib—Weight decreased—Prednisone—multiple sclerosis	0.000375	0.00215	CcSEcCtD
Afatinib—Mental disorder—Methylprednisolone—multiple sclerosis	0.000367	0.0021	CcSEcCtD
Afatinib—Malnutrition—Methylprednisolone—multiple sclerosis	0.000365	0.00209	CcSEcCtD
Afatinib—Dysgeusia—Triamcinolone—multiple sclerosis	0.000358	0.00205	CcSEcCtD
Afatinib—Nausea—Cladribine—multiple sclerosis	0.000357	0.00205	CcSEcCtD
Afatinib—Eye disorder—Betamethasone—multiple sclerosis	0.000356	0.00204	CcSEcCtD
Afatinib—Eye disorder—Dexamethasone—multiple sclerosis	0.000356	0.00204	CcSEcCtD
Afatinib—Back pain—Triamcinolone—multiple sclerosis	0.000354	0.00202	CcSEcCtD
Afatinib—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000353	0.00202	CcSEcCtD
Afatinib—ABCB1—medulla oblongata—multiple sclerosis	0.00035	0.00421	CbGeAlD
Afatinib—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000348	0.00199	CcSEcCtD
Afatinib—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000344	0.00197	CcSEcCtD
Afatinib—Fatigue—Mitoxantrone—multiple sclerosis	0.000341	0.00195	CcSEcCtD
Afatinib—Constipation—Mitoxantrone—multiple sclerosis	0.000338	0.00194	CcSEcCtD
Afatinib—Alopecia—Betamethasone—multiple sclerosis	0.000337	0.00193	CcSEcCtD
Afatinib—Alopecia—Dexamethasone—multiple sclerosis	0.000337	0.00193	CcSEcCtD
Afatinib—Diarrhoea—Azathioprine—multiple sclerosis	0.000335	0.00192	CcSEcCtD
Afatinib—Connective tissue disorder—Prednisone—multiple sclerosis	0.000326	0.00187	CcSEcCtD
Afatinib—Dizziness—Azathioprine—multiple sclerosis	0.000324	0.00185	CcSEcCtD
Afatinib—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000322	0.00184	CcSEcCtD
Afatinib—ABCB1—midbrain—multiple sclerosis	0.000319	0.00384	CbGeAlD
Afatinib—Cough—Triamcinolone—multiple sclerosis	0.000319	0.00183	CcSEcCtD
Afatinib—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000313	0.00179	CcSEcCtD
Afatinib—ABCB1—spinal cord—multiple sclerosis	0.000312	0.00375	CbGeAlD
Afatinib—Vomiting—Azathioprine—multiple sclerosis	0.000311	0.00178	CcSEcCtD
Afatinib—Pneumonia—Methotrexate—multiple sclerosis	0.000311	0.00178	CcSEcCtD
Afatinib—Eye disorder—Prednisone—multiple sclerosis	0.00031	0.00178	CcSEcCtD
Afatinib—Infestation NOS—Methotrexate—multiple sclerosis	0.000309	0.00177	CcSEcCtD
Afatinib—Infestation—Methotrexate—multiple sclerosis	0.000309	0.00177	CcSEcCtD
Afatinib—Rash—Azathioprine—multiple sclerosis	0.000309	0.00177	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000309	0.00177	CcSEcCtD
Afatinib—Dermatitis—Azathioprine—multiple sclerosis	0.000308	0.00176	CcSEcCtD
Afatinib—Headache—Azathioprine—multiple sclerosis	0.000307	0.00175	CcSEcCtD
Afatinib—Renal failure—Methotrexate—multiple sclerosis	0.000304	0.00174	CcSEcCtD
Afatinib—Stomatitis—Methotrexate—multiple sclerosis	0.000301	0.00172	CcSEcCtD
Afatinib—Conjunctivitis—Methotrexate—multiple sclerosis	0.0003	0.00172	CcSEcCtD
Afatinib—Infection—Triamcinolone—multiple sclerosis	0.000297	0.0017	CcSEcCtD
Afatinib—Infection—Methylprednisolone—multiple sclerosis	0.000296	0.00169	CcSEcCtD
Afatinib—Insomnia—Prednisolone—multiple sclerosis	0.000294	0.00168	CcSEcCtD
Afatinib—Alopecia—Prednisone—multiple sclerosis	0.000293	0.00168	CcSEcCtD
Afatinib—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000292	0.00167	CcSEcCtD
Afatinib—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000292	0.00167	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—multiple sclerosis	0.000291	0.00167	CcSEcCtD
Afatinib—Mental disorder—Prednisone—multiple sclerosis	0.000291	0.00166	CcSEcCtD
Afatinib—Nausea—Azathioprine—multiple sclerosis	0.000291	0.00166	CcSEcCtD
Afatinib—Skin disorder—Methylprednisolone—multiple sclerosis	0.000289	0.00166	CcSEcCtD
Afatinib—Malnutrition—Prednisone—multiple sclerosis	0.000289	0.00165	CcSEcCtD
Afatinib—Asthenia—Mitoxantrone—multiple sclerosis	0.000284	0.00162	CcSEcCtD
Afatinib—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000274	0.00157	CcSEcCtD
Afatinib—Urethral disorder—Methotrexate—multiple sclerosis	0.000272	0.00156	CcSEcCtD
Afatinib—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000271	0.00155	CcSEcCtD
Afatinib—Insomnia—Triamcinolone—multiple sclerosis	0.00027	0.00155	CcSEcCtD
Afatinib—Insomnia—Methylprednisolone—multiple sclerosis	0.000269	0.00154	CcSEcCtD
Afatinib—Infection—Dexamethasone—multiple sclerosis	0.000269	0.00154	CcSEcCtD
Afatinib—Infection—Betamethasone—multiple sclerosis	0.000269	0.00154	CcSEcCtD
Afatinib—Dyspnoea—Triamcinolone—multiple sclerosis	0.000266	0.00152	CcSEcCtD
Afatinib—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000266	0.00152	CcSEcCtD
Afatinib—Nervous system disorder—Betamethasone—multiple sclerosis	0.000266	0.00152	CcSEcCtD
Afatinib—Dyspepsia—Triamcinolone—multiple sclerosis	0.000263	0.0015	CcSEcCtD
Afatinib—ABCB1—nervous system—multiple sclerosis	0.000263	0.00316	CbGeAlD
Afatinib—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000262	0.0015	CcSEcCtD
Afatinib—Eye disorder—Methotrexate—multiple sclerosis	0.000259	0.00148	CcSEcCtD
Afatinib—Fatigue—Triamcinolone—multiple sclerosis	0.000257	0.00147	CcSEcCtD
Afatinib—Fatigue—Methylprednisolone—multiple sclerosis	0.000257	0.00147	CcSEcCtD
Afatinib—ABCB1—central nervous system—multiple sclerosis	0.000253	0.00304	CbGeAlD
Afatinib—Vomiting—Mitoxantrone—multiple sclerosis	0.000252	0.00144	CcSEcCtD
Afatinib—Mediastinal disorder—Methotrexate—multiple sclerosis	0.00025	0.00143	CcSEcCtD
Afatinib—Rash—Mitoxantrone—multiple sclerosis	0.000249	0.00143	CcSEcCtD
Afatinib—Dermatitis—Mitoxantrone—multiple sclerosis	0.000249	0.00143	CcSEcCtD
Afatinib—Headache—Mitoxantrone—multiple sclerosis	0.000248	0.00142	CcSEcCtD
Afatinib—ABCB1—cerebellum—multiple sclerosis	0.000247	0.00297	CbGeAlD
Afatinib—Alopecia—Methotrexate—multiple sclerosis	0.000245	0.0014	CcSEcCtD
Afatinib—Insomnia—Dexamethasone—multiple sclerosis	0.000245	0.0014	CcSEcCtD
Afatinib—Insomnia—Betamethasone—multiple sclerosis	0.000245	0.0014	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000244	0.0014	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—multiple sclerosis	0.000243	0.00139	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—multiple sclerosis	0.000242	0.00138	CcSEcCtD
Afatinib—Dyspepsia—Betamethasone—multiple sclerosis	0.000238	0.00136	CcSEcCtD
Afatinib—Dyspepsia—Dexamethasone—multiple sclerosis	0.000238	0.00136	CcSEcCtD
Afatinib—Dysgeusia—Methotrexate—multiple sclerosis	0.000237	0.00135	CcSEcCtD
Afatinib—Body temperature increased—Triamcinolone—multiple sclerosis	0.000236	0.00135	CcSEcCtD
Afatinib—Decreased appetite—Betamethasone—multiple sclerosis	0.000235	0.00135	CcSEcCtD
Afatinib—Decreased appetite—Dexamethasone—multiple sclerosis	0.000235	0.00135	CcSEcCtD
Afatinib—Nausea—Mitoxantrone—multiple sclerosis	0.000235	0.00135	CcSEcCtD
Afatinib—Infection—Prednisone—multiple sclerosis	0.000234	0.00134	CcSEcCtD
Afatinib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000234	0.00134	CcSEcCtD
Afatinib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000234	0.00134	CcSEcCtD
Afatinib—Back pain—Methotrexate—multiple sclerosis	0.000234	0.00134	CcSEcCtD
Afatinib—Fatigue—Dexamethasone—multiple sclerosis	0.000233	0.00134	CcSEcCtD
Afatinib—Fatigue—Betamethasone—multiple sclerosis	0.000233	0.00134	CcSEcCtD
Afatinib—Nervous system disorder—Prednisone—multiple sclerosis	0.000231	0.00132	CcSEcCtD
Afatinib—Skin disorder—Prednisone—multiple sclerosis	0.000229	0.00131	CcSEcCtD
Afatinib—Dizziness—Prednisolone—multiple sclerosis	0.000215	0.00123	CcSEcCtD
Afatinib—Asthenia—Triamcinolone—multiple sclerosis	0.000214	0.00123	CcSEcCtD
Afatinib—Body temperature increased—Betamethasone—multiple sclerosis	0.000214	0.00123	CcSEcCtD
Afatinib—Body temperature increased—Dexamethasone—multiple sclerosis	0.000214	0.00123	CcSEcCtD
Afatinib—Asthenia—Methylprednisolone—multiple sclerosis	0.000214	0.00122	CcSEcCtD
Afatinib—Insomnia—Prednisone—multiple sclerosis	0.000213	0.00122	CcSEcCtD
Afatinib—Pruritus—Triamcinolone—multiple sclerosis	0.000211	0.00121	CcSEcCtD
Afatinib—Cough—Methotrexate—multiple sclerosis	0.000211	0.00121	CcSEcCtD
Afatinib—Pruritus—Methylprednisolone—multiple sclerosis	0.000211	0.00121	CcSEcCtD
Afatinib—Dyspepsia—Prednisone—multiple sclerosis	0.000208	0.00119	CcSEcCtD
Afatinib—Decreased appetite—Prednisone—multiple sclerosis	0.000205	0.00117	CcSEcCtD
Afatinib—Rash—Prednisolone—multiple sclerosis	0.000205	0.00117	CcSEcCtD
Afatinib—Dermatitis—Prednisolone—multiple sclerosis	0.000204	0.00117	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000204	0.00117	CcSEcCtD
Afatinib—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000204	0.00117	CcSEcCtD
Afatinib—Fatigue—Prednisone—multiple sclerosis	0.000203	0.00116	CcSEcCtD
Afatinib—Headache—Prednisolone—multiple sclerosis	0.000203	0.00116	CcSEcCtD
Afatinib—Vandetanib—ALB—multiple sclerosis	0.000202	0.513	CrCbGaD
Afatinib—Constipation—Prednisone—multiple sclerosis	0.000202	0.00115	CcSEcCtD
Afatinib—ABCB1—brain—multiple sclerosis	0.000201	0.00242	CbGeAlD
Afatinib—Dizziness—Triamcinolone—multiple sclerosis	0.000197	0.00113	CcSEcCtD
Afatinib—Dizziness—Methylprednisolone—multiple sclerosis	0.000197	0.00113	CcSEcCtD
Afatinib—Infection—Methotrexate—multiple sclerosis	0.000196	0.00112	CcSEcCtD
Afatinib—Asthenia—Dexamethasone—multiple sclerosis	0.000194	0.00111	CcSEcCtD
Afatinib—Asthenia—Betamethasone—multiple sclerosis	0.000194	0.00111	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—multiple sclerosis	0.000193	0.00111	CcSEcCtD
Afatinib—Nausea—Prednisolone—multiple sclerosis	0.000193	0.0011	CcSEcCtD
Afatinib—Gefitinib—ALB—multiple sclerosis	0.000192	0.487	CrCbGaD
Afatinib—Pruritus—Dexamethasone—multiple sclerosis	0.000192	0.0011	CcSEcCtD
Afatinib—Pruritus—Betamethasone—multiple sclerosis	0.000192	0.0011	CcSEcCtD
Afatinib—Skin disorder—Methotrexate—multiple sclerosis	0.000191	0.0011	CcSEcCtD
Afatinib—Vomiting—Triamcinolone—multiple sclerosis	0.00019	0.00109	CcSEcCtD
Afatinib—Vomiting—Methylprednisolone—multiple sclerosis	0.000189	0.00108	CcSEcCtD
Afatinib—Rash—Triamcinolone—multiple sclerosis	0.000188	0.00108	CcSEcCtD
Afatinib—Dermatitis—Triamcinolone—multiple sclerosis	0.000188	0.00108	CcSEcCtD
Afatinib—Rash—Methylprednisolone—multiple sclerosis	0.000188	0.00107	CcSEcCtD
Afatinib—Dermatitis—Methylprednisolone—multiple sclerosis	0.000188	0.00107	CcSEcCtD
Afatinib—Headache—Triamcinolone—multiple sclerosis	0.000187	0.00107	CcSEcCtD
Afatinib—Headache—Methylprednisolone—multiple sclerosis	0.000187	0.00107	CcSEcCtD
Afatinib—Body temperature increased—Prednisone—multiple sclerosis	0.000186	0.00107	CcSEcCtD
Afatinib—Diarrhoea—Betamethasone—multiple sclerosis	0.000185	0.00106	CcSEcCtD
Afatinib—Diarrhoea—Dexamethasone—multiple sclerosis	0.000185	0.00106	CcSEcCtD
Afatinib—Dizziness—Dexamethasone—multiple sclerosis	0.000179	0.00103	CcSEcCtD
Afatinib—Dizziness—Betamethasone—multiple sclerosis	0.000179	0.00103	CcSEcCtD
Afatinib—Insomnia—Methotrexate—multiple sclerosis	0.000178	0.00102	CcSEcCtD
Afatinib—Nausea—Triamcinolone—multiple sclerosis	0.000177	0.00101	CcSEcCtD
Afatinib—Nausea—Methylprednisolone—multiple sclerosis	0.000177	0.00101	CcSEcCtD
Afatinib—Dyspnoea—Methotrexate—multiple sclerosis	0.000176	0.00101	CcSEcCtD
Afatinib—Dyspepsia—Methotrexate—multiple sclerosis	0.000174	0.000993	CcSEcCtD
Afatinib—Vomiting—Dexamethasone—multiple sclerosis	0.000172	0.000986	CcSEcCtD
Afatinib—Vomiting—Betamethasone—multiple sclerosis	0.000172	0.000986	CcSEcCtD
Afatinib—Decreased appetite—Methotrexate—multiple sclerosis	0.000171	0.000981	CcSEcCtD
Afatinib—Rash—Betamethasone—multiple sclerosis	0.000171	0.000977	CcSEcCtD
Afatinib—Rash—Dexamethasone—multiple sclerosis	0.000171	0.000977	CcSEcCtD
Afatinib—Dermatitis—Betamethasone—multiple sclerosis	0.000171	0.000977	CcSEcCtD
Afatinib—Dermatitis—Dexamethasone—multiple sclerosis	0.000171	0.000977	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.00017	0.000974	CcSEcCtD
Afatinib—Fatigue—Methotrexate—multiple sclerosis	0.00017	0.000973	CcSEcCtD
Afatinib—Headache—Dexamethasone—multiple sclerosis	0.00017	0.000971	CcSEcCtD
Afatinib—Headache—Betamethasone—multiple sclerosis	0.00017	0.000971	CcSEcCtD
Afatinib—Asthenia—Prednisone—multiple sclerosis	0.000169	0.000969	CcSEcCtD
Afatinib—Pruritus—Prednisone—multiple sclerosis	0.000167	0.000955	CcSEcCtD
Afatinib—Diarrhoea—Prednisone—multiple sclerosis	0.000161	0.000924	CcSEcCtD
Afatinib—Nausea—Dexamethasone—multiple sclerosis	0.000161	0.000921	CcSEcCtD
Afatinib—Nausea—Betamethasone—multiple sclerosis	0.000161	0.000921	CcSEcCtD
Afatinib—Dizziness—Prednisone—multiple sclerosis	0.000156	0.000893	CcSEcCtD
Afatinib—Body temperature increased—Methotrexate—multiple sclerosis	0.000156	0.000892	CcSEcCtD
Afatinib—Vomiting—Prednisone—multiple sclerosis	0.00015	0.000858	CcSEcCtD
Afatinib—Rash—Prednisone—multiple sclerosis	0.000149	0.000851	CcSEcCtD
Afatinib—Dermatitis—Prednisone—multiple sclerosis	0.000149	0.00085	CcSEcCtD
Afatinib—Headache—Prednisone—multiple sclerosis	0.000148	0.000846	CcSEcCtD
Afatinib—Asthenia—Methotrexate—multiple sclerosis	0.000141	0.00081	CcSEcCtD
Afatinib—Nausea—Prednisone—multiple sclerosis	0.00014	0.000802	CcSEcCtD
Afatinib—Pruritus—Methotrexate—multiple sclerosis	0.000139	0.000798	CcSEcCtD
Afatinib—Diarrhoea—Methotrexate—multiple sclerosis	0.000135	0.000772	CcSEcCtD
Afatinib—Dizziness—Methotrexate—multiple sclerosis	0.00013	0.000746	CcSEcCtD
Afatinib—Vomiting—Methotrexate—multiple sclerosis	0.000125	0.000717	CcSEcCtD
Afatinib—Rash—Methotrexate—multiple sclerosis	0.000124	0.000711	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—multiple sclerosis	0.000124	0.000711	CcSEcCtD
Afatinib—Headache—Methotrexate—multiple sclerosis	0.000123	0.000707	CcSEcCtD
Afatinib—Nausea—Methotrexate—multiple sclerosis	0.000117	0.00067	CcSEcCtD
Afatinib—ABL1—Immune System—IL2RA—multiple sclerosis	2.01e-05	6.95e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—TYK2—multiple sclerosis	2e-05	6.92e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-A—multiple sclerosis	1.98e-05	6.87e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL1B—multiple sclerosis	1.98e-05	6.85e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—MAPK1—multiple sclerosis	1.97e-05	6.83e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL2—multiple sclerosis	1.97e-05	6.82e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-DQB1—multiple sclerosis	1.96e-05	6.8e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD86—multiple sclerosis	1.96e-05	6.79e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL3—multiple sclerosis	1.93e-05	6.68e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—STAT3—multiple sclerosis	1.92e-05	6.66e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD40LG—multiple sclerosis	1.92e-05	6.66e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CD80—multiple sclerosis	1.91e-05	6.63e-05	CbGpPWpGaD
Afatinib—ABCG2—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.91e-05	6.61e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CCR5—multiple sclerosis	1.9e-05	6.59e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD8A—multiple sclerosis	1.9e-05	6.58e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—BCHE—multiple sclerosis	1.9e-05	6.57e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CD86—multiple sclerosis	1.9e-05	6.57e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CD86—multiple sclerosis	1.89e-05	6.54e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CD80—multiple sclerosis	1.89e-05	6.53e-05	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—IL6—multiple sclerosis	1.88e-05	6.52e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL2RA—multiple sclerosis	1.88e-05	6.5e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CD4—multiple sclerosis	1.88e-05	6.49e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCL5—multiple sclerosis	1.87e-05	6.46e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL3—multiple sclerosis	1.86e-05	6.44e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTGER4—multiple sclerosis	1.86e-05	6.43e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CD40LG—multiple sclerosis	1.85e-05	6.42e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—MMP9—multiple sclerosis	1.85e-05	6.4e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—IL2—multiple sclerosis	1.85e-05	6.4e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CD8A—multiple sclerosis	1.83e-05	6.35e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-B—multiple sclerosis	1.83e-05	6.33e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PGR—multiple sclerosis	1.83e-05	6.33e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—POMC—multiple sclerosis	1.82e-05	6.3e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—TLR4—multiple sclerosis	1.82e-05	6.28e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-DRB1—multiple sclerosis	1.81e-05	6.27e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CD86—multiple sclerosis	1.81e-05	6.27e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CD4—multiple sclerosis	1.81e-05	6.26e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—TYK2—multiple sclerosis	1.81e-05	6.25e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD4—multiple sclerosis	1.8e-05	6.24e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCR3—multiple sclerosis	1.79e-05	6.21e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—POMC—multiple sclerosis	1.79e-05	6.2e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTGER4—multiple sclerosis	1.79e-05	6.2e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—RRM1—multiple sclerosis	1.79e-05	6.19e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TGFB1—multiple sclerosis	1.78e-05	6.18e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CCL2—multiple sclerosis	1.78e-05	6.16e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—IL6—multiple sclerosis	1.78e-05	6.16e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CD28—multiple sclerosis	1.78e-05	6.15e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-B—multiple sclerosis	1.76e-05	6.1e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PGR—multiple sclerosis	1.76e-05	6.1e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CCL2—multiple sclerosis	1.75e-05	6.07e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TGFB1—multiple sclerosis	1.75e-05	6.06e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—STAT3—multiple sclerosis	1.75e-05	6.06e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—MAPK1—multiple sclerosis	1.75e-05	6.06e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCR2—multiple sclerosis	1.75e-05	6.04e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CD86—multiple sclerosis	1.75e-05	6.04e-05	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IL6—multiple sclerosis	1.74e-05	6.03e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—ICAM1—multiple sclerosis	1.74e-05	6.02e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD4—multiple sclerosis	1.74e-05	6.01e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SPP1—multiple sclerosis	1.73e-05	5.99e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCR3—multiple sclerosis	1.73e-05	5.99e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—STAT3—multiple sclerosis	1.72e-05	5.97e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—MAPK1—multiple sclerosis	1.72e-05	5.94e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2RA—multiple sclerosis	1.72e-05	5.94e-05	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—IL6—multiple sclerosis	1.71e-05	5.93e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CD28—multiple sclerosis	1.71e-05	5.93e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-A—multiple sclerosis	1.7e-05	5.87e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IFNG—multiple sclerosis	1.69e-05	5.86e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCR2—multiple sclerosis	1.68e-05	5.82e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCR5—multiple sclerosis	1.68e-05	5.82e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD80—multiple sclerosis	1.68e-05	5.8e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TNF—multiple sclerosis	1.67e-05	5.77e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—STAT3—multiple sclerosis	1.66e-05	5.74e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2RA—multiple sclerosis	1.66e-05	5.74e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2RA—multiple sclerosis	1.65e-05	5.72e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.65e-05	5.71e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.65e-05	5.7e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—STAT3—multiple sclerosis	1.64e-05	5.69e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD4—multiple sclerosis	1.63e-05	5.66e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-A—multiple sclerosis	1.63e-05	5.66e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TYK2—multiple sclerosis	1.62e-05	5.59e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—STAT3—multiple sclerosis	1.62e-05	5.59e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.61e-05	5.59e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CNR1—multiple sclerosis	1.61e-05	5.58e-05	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—IL6—multiple sclerosis	1.61e-05	5.57e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CCR5—multiple sclerosis	1.61e-05	5.56e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TYK2—multiple sclerosis	1.59e-05	5.51e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—STAT3—multiple sclerosis	1.59e-05	5.51e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—MAPK1—multiple sclerosis	1.59e-05	5.51e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—MAPK1—multiple sclerosis	1.57e-05	5.42e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HLA-A—multiple sclerosis	1.57e-05	5.42e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CNR1—multiple sclerosis	1.55e-05	5.37e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—TLR4—multiple sclerosis	1.55e-05	5.37e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-DRB1—multiple sclerosis	1.55e-05	5.36e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CCR5—multiple sclerosis	1.55e-05	5.36e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—MAPK1—multiple sclerosis	1.55e-05	5.35e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.54e-05	5.32e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—APOE—multiple sclerosis	1.53e-05	5.3e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TGFB1—multiple sclerosis	1.52e-05	5.28e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—IL6—multiple sclerosis	1.52e-05	5.25e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL1B—multiple sclerosis	1.51e-05	5.22e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HLA-A—multiple sclerosis	1.51e-05	5.22e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—MAPK1—multiple sclerosis	1.51e-05	5.22e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL2—multiple sclerosis	1.5e-05	5.2e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—MYC—multiple sclerosis	1.5e-05	5.2e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—TGFB1—multiple sclerosis	1.5e-05	5.18e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—MAPK1—multiple sclerosis	1.5e-05	5.17e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—TLR4—multiple sclerosis	1.49e-05	5.17e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-DRB1—multiple sclerosis	1.49e-05	5.17e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—POMC—multiple sclerosis	1.49e-05	5.15e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—ICAM1—multiple sclerosis	1.49e-05	5.15e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—MYC—multiple sclerosis	1.48e-05	5.12e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—TGFB1—multiple sclerosis	1.48e-05	5.11e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—MAPK1—multiple sclerosis	1.47e-05	5.08e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—APOE—multiple sclerosis	1.46e-05	5.06e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CCL2—multiple sclerosis	1.46e-05	5.04e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL10—multiple sclerosis	1.45e-05	5.02e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—MAPK1—multiple sclerosis	1.45e-05	5.01e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TGFB1—multiple sclerosis	1.44e-05	4.99e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ICAM1—multiple sclerosis	1.43e-05	4.96e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD80—multiple sclerosis	1.43e-05	4.95e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TNF—multiple sclerosis	1.42e-05	4.93e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—TYK2—multiple sclerosis	1.41e-05	4.89e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—MAPK1—multiple sclerosis	1.41e-05	4.89e-05	CbGpPWpGaD
Afatinib—LCK—Disease—APOE—multiple sclerosis	1.41e-05	4.88e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL10—multiple sclerosis	1.4e-05	4.84e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CD80—multiple sclerosis	1.38e-05	4.79e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CD80—multiple sclerosis	1.38e-05	4.77e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL2—multiple sclerosis	1.34e-05	4.65e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—IL6—multiple sclerosis	1.34e-05	4.65e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL2—multiple sclerosis	1.32e-05	4.58e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IFNG—multiple sclerosis	1.32e-05	4.58e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—TYK2—multiple sclerosis	1.32e-05	4.58e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CD80—multiple sclerosis	1.32e-05	4.57e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—MAPK1—multiple sclerosis	1.32e-05	4.57e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—POMC—multiple sclerosis	1.32e-05	4.55e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCL2—multiple sclerosis	1.29e-05	4.45e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD4—multiple sclerosis	1.28e-05	4.43e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CD80—multiple sclerosis	1.27e-05	4.41e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MMP9—multiple sclerosis	1.27e-05	4.4e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—MAPK1—multiple sclerosis	1.27e-05	4.4e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CD86—multiple sclerosis	1.27e-05	4.39e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—STAT3—multiple sclerosis	1.27e-05	4.38e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MMP9—multiple sclerosis	1.25e-05	4.34e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL5—multiple sclerosis	1.25e-05	4.32e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CD86—multiple sclerosis	1.22e-05	4.23e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL6—multiple sclerosis	1.22e-05	4.23e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—TYK2—multiple sclerosis	1.21e-05	4.18e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL6—multiple sclerosis	1.2e-05	4.17e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL5—multiple sclerosis	1.2e-05	4.17e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—IL6—multiple sclerosis	1.19e-05	4.11e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL1B—multiple sclerosis	1.18e-05	4.09e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL2—multiple sclerosis	1.18e-05	4.07e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TYK2—multiple sclerosis	1.17e-05	4.04e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—TYK2—multiple sclerosis	1.16e-05	4.03e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL6—multiple sclerosis	1.16e-05	4.01e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SPP1—multiple sclerosis	1.16e-05	4e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—MAPK1—multiple sclerosis	1.15e-05	3.98e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—IL6—multiple sclerosis	1.15e-05	3.98e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—APOE—multiple sclerosis	1.14e-05	3.96e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—STAT3—multiple sclerosis	1.13e-05	3.92e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IFNG—multiple sclerosis	1.13e-05	3.92e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—IL6—multiple sclerosis	1.13e-05	3.91e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCR5—multiple sclerosis	1.13e-05	3.89e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TYK2—multiple sclerosis	1.12e-05	3.86e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—STAT3—multiple sclerosis	1.11e-05	3.86e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SPP1—multiple sclerosis	1.11e-05	3.86e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—IL6—multiple sclerosis	1.11e-05	3.85e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2RA—multiple sclerosis	1.11e-05	3.84e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL2—multiple sclerosis	1.1e-05	3.81e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD4—multiple sclerosis	1.09e-05	3.78e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IFNG—multiple sclerosis	1.09e-05	3.77e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCR5—multiple sclerosis	1.08e-05	3.75e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TYK2—multiple sclerosis	1.08e-05	3.72e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2RA—multiple sclerosis	1.07e-05	3.7e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CD4—multiple sclerosis	1.05e-05	3.64e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MYC—multiple sclerosis	1.05e-05	3.64e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TGFB1—multiple sclerosis	1.05e-05	3.63e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—multiple sclerosis	1.04e-05	3.58e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.03e-05	3.58e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TGFB1—multiple sclerosis	1.03e-05	3.58e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MAPK1—multiple sclerosis	1.03e-05	3.56e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—BCHE—multiple sclerosis	1.03e-05	3.55e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOE—multiple sclerosis	1.02e-05	3.54e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—multiple sclerosis	1.01e-05	3.51e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MAPK1—multiple sclerosis	1.01e-05	3.51e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1B—multiple sclerosis	1.01e-05	3.49e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CD4—multiple sclerosis	1.01e-05	3.49e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2—multiple sclerosis	1.01e-05	3.48e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—multiple sclerosis	9.9e-06	3.43e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOE—multiple sclerosis	9.86e-06	3.41e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—POMC—multiple sclerosis	9.82e-06	3.4e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—multiple sclerosis	9.78e-06	3.38e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1B—multiple sclerosis	9.73e-06	3.37e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CD4—multiple sclerosis	9.72e-06	3.37e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—multiple sclerosis	9.72e-06	3.36e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—multiple sclerosis	9.69e-06	3.35e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CD80—multiple sclerosis	9.26e-06	3.2e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—multiple sclerosis	9.2e-06	3.18e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK1—multiple sclerosis	9e-06	3.12e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ALB—multiple sclerosis	8.95e-06	3.1e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CD80—multiple sclerosis	8.92e-06	3.09e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—multiple sclerosis	8.84e-06	3.06e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—POMC—multiple sclerosis	8.79e-06	3.04e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL2—multiple sclerosis	8.6e-06	2.98e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—POMC—multiple sclerosis	8.47e-06	2.93e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—multiple sclerosis	8.46e-06	2.93e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—MAPK1—multiple sclerosis	8.42e-06	2.91e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL2—multiple sclerosis	8.29e-06	2.87e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—multiple sclerosis	8.18e-06	2.83e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—multiple sclerosis	8.15e-06	2.82e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—multiple sclerosis	7.9e-06	2.74e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TYK2—multiple sclerosis	7.81e-06	2.7e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—multiple sclerosis	7.81e-06	2.7e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—multiple sclerosis	7.79e-06	2.69e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK1—multiple sclerosis	7.69e-06	2.66e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—multiple sclerosis	7.6e-06	2.63e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TGFB1—multiple sclerosis	7.58e-06	2.62e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TYK2—multiple sclerosis	7.53e-06	2.61e-05	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—multiple sclerosis	7.53e-06	2.61e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK1—multiple sclerosis	7.44e-06	2.57e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK1—multiple sclerosis	7.41e-06	2.57e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—multiple sclerosis	7.26e-06	2.51e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFB1—multiple sclerosis	7.24e-06	2.51e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MAPK1—multiple sclerosis	7.1e-06	2.46e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—multiple sclerosis	7e-06	2.42e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TGFB1—multiple sclerosis	6.98e-06	2.42e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—multiple sclerosis	6.92e-06	2.39e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MAPK1—multiple sclerosis	6.84e-06	2.37e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—multiple sclerosis	6.5e-06	2.25e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—multiple sclerosis	6.47e-06	2.24e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—multiple sclerosis	6.27e-06	2.17e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOE—multiple sclerosis	6.18e-06	2.14e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—multiple sclerosis	6.15e-06	2.13e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—multiple sclerosis	5.93e-06	2.05e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—multiple sclerosis	5.91e-06	2.05e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—multiple sclerosis	5.71e-06	1.98e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—multiple sclerosis	5.7e-06	1.97e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—multiple sclerosis	5.47e-06	1.89e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—multiple sclerosis	5.46e-06	1.89e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—POMC—multiple sclerosis	5.31e-06	1.84e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—multiple sclerosis	5.27e-06	1.82e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—multiple sclerosis	5.26e-06	1.82e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—multiple sclerosis	5.08e-06	1.76e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TGFB1—multiple sclerosis	5.07e-06	1.75e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK1—multiple sclerosis	4.97e-06	1.72e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—multiple sclerosis	4.9e-06	1.7e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFB1—multiple sclerosis	4.89e-06	1.69e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALB—multiple sclerosis	4.84e-06	1.67e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK1—multiple sclerosis	4.79e-06	1.66e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—multiple sclerosis	3.82e-06	1.32e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—multiple sclerosis	3.68e-06	1.27e-05	CbGpPWpGaD
